[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349932-105":59,"doc-detail-349932-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-comprehensive-functional-atlas-of-alk-kinase-domain-variants-reveals-resistance-landscape-to-alk-inhibitors","A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors","","A comprehensive functional atlas maps how ALK tyrosine kinase domain variants change drug resistance under selective pressure. The work addresses ALK fusion–driven cancers in which responses to ALK TKIs are ultimately limited by acquired resistance, often from single nucleotide variants within the ALK kinase domain, including variants of uncertain significance (VUS). Using prime editing, the study generates 3,208 ALK variants spanning exons 20–28 and evaluates resistance across three TKI generations, producing high-resolution resistance landscapes linked to structural features and ATP-binding and distal regions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-comprehensive-functional-atlas-of-alk-kinase-domain-variants-reveals-resistance-landscape-to-alk-inhibitors/349932/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-comprehensive-functional-atlas-of-alk-kinase-domain-variants-reveals-resistance-landscape-to-alk-inhibitors/349932.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address regarding ALK mutations and ALK inhibitors?","Question",{"text":112,"@type":113},"Resistance to ALK tyrosine kinase inhibitors commonly arises from single nucleotide variants in the ALK kinase domain, many of which are variants of uncertain significance (VUS). The study aims to systematically profile how these variants affect resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the ALK variants generated for resistance profiling?",{"text":117,"@type":113},"Prime editing was used to generate and assess 3,208 ALK variants, covering 99% of all possible SNVs across exons 20–28, plus intronic variants.",{"name":119,"@type":110,"acceptedAnswer":120},"Which ALK inhibitor generations were evaluated and what outputs were produced?",{"text":121,"@type":113},"Drug resistance was evaluated across three generations of ALK TKIs: alectinib, lorlatinib, and zotizalkib. The study produces high-resolution resistance landscapes that validate known resistance mutations and identify previously uncharacterized VUSs and shared or drug-specific resistance patterns.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349932,1790975619,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Oh et al. Genome Biology (2026) 27:72 [https://doi.org/10.1186/s13059-026-03977-4](https://doi.org/10.1186/s13059-026-03977-4)  \nGenome Biology  \nRESEARCH Open Access  \nA comprehensive functional atlas ofALK kinase domain variants reveals resistance landscape to ALK inhibitors  \nHyeong-Cheol Oh 1,2†, Yeonseung Han1†, Yoojin Chang1,3† and Hyongbum Henry Kim1,3,4,5,6,7,8,9,10*  \n\n| †Hyeong-Cheol Oh, Yeonseung Han andYoojin Chang contributed equally to this work. |\n| --- |\n| *Correspondence: [hkim1@yuhs.ac](hkim1@yuhs.ac) |\n\n1 Department of Pharmacology, Yonsei University College of Medicine, Seoul, Republic of Korea  \nFull list of author information is available at the end of the article  \nAbstract  \nBackground: ALK gene fusions are key oncogenic drivers in cancers such as non-small cell lung cancer, where they define a molecular subtype responsive to ALK tyrosine kinase inhibitors (TKIs) . However, resistance commonly arises due to single nucleotide variants (SNVs) within the ALK tyrosine kinase domain, many of which remain variants of uncertain significance (VUSs) .  \nResults: To systematically profile resistance, we use prime editing to generate and assess 3,208 ALK variants covering 99% of all possible SNVs across exons 20–28, along with intronic variants. We evaluate drug resistance across three generations of ALKTKIs: alectinib, lorlatinib, and zotizalkib. These high-resolution resistance landscapes validate known resistance mutations (e. g., G1202R, L1196M), identify previously uncharacterized resistance-associated VUSs, and reveal distinct patterns of drug-specific and shared resistance across inhibitors. Structural mapping further contextualizes resistance-associated variants relative to the ATP-binding pocket and distal regions associated with resistance.  \nConclusions: This study provides a comprehensive functional atlas of ALK tyrosine kinase domain variants under TKI selection, offering a valuable experimental framework for interpreting resistance-associated variants. Although derived from in vitro models and therefore context dependent, this resource complements existing clinical and genomic knowledge and may aid in the functional interpretation ofALK variants observed in ALK-driven cancers.  \nKeywords: ALK fusion variants, Prime editing screening, Variants of uncertain significance  \nBackground  \nALK gene fusions play a critical role in the pathogenesis of various cancers [1, 2], including non-small cell lung cancer (NSCLC) [3], anaplastic large cell lymphoma (ALCL)[4, 5], inflammatory myofibroblastic tumor (IMT) [6], breast cancer [7], colorectal cancer [7], and glioma [8, 9]. In particular, ALK fusions define distinct molecular  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nOh et al. Genome Biology (2026) 27:72 Page 2 of 29  \nsubtypes of NSCLC, accounting for approximately 4–6% of lung adenocarcinomas [3, 10]. These fusions","cbCaieRz5jnexKXL","https://ap.wps.com/l/cbCaieRz5jnexKXL","pdf",2319045,29,"English","# Abstract\n## Background\n## Results\n## Conclusions\n# Keywords\n# Background (context)\n## ALK fusions and cancer subtype roles\n## ALK TKIs and emergence of resistance\n## Need for comprehensive resistance profiles","[{\"question\":\"What problem does the study address regarding ALK mutations and ALK inhibitors?\",\"answer\":\"Resistance to ALK tyrosine kinase inhibitors commonly arises from single nucleotide variants in the ALK kinase domain, many of which are variants of uncertain significance (VUS). The study aims to systematically profile how these variants affect resistance.\"},{\"question\":\"How were the ALK variants generated for resistance profiling?\",\"answer\":\"Prime editing was used to generate and assess 3,208 ALK variants, covering 99% of all possible SNVs across exons 20–28, plus intronic variants.\"},{\"question\":\"Which ALK inhibitor generations were evaluated and what outputs were produced?\",\"answer\":\"Drug resistance was evaluated across three generations of ALK TKIs: alectinib, lorlatinib, and zotizalkib. The study produces high-resolution resistance landscapes that validate known resistance mutations and identify previously uncharacterized VUSs and shared or drug-specific resistance patterns.\"}]","A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors | PDF",1790086317,73,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1581934e425945bdc11e68dc87d81ce.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9917bb9d8ff89e89664d617ebcdc053b.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72c11a1b602ce7ed8c52ddebc4d102e9.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd84a08f0ff5af124b1bf7897d3902bf.webp",980,1301]